Posted by Michael Wonder on 20 Aug 2020
New agreement means NICE recommends combination treatment for some lymphoma patients
20 August 2020 - Hundreds of people with a form of blood cancer will benefit from a new treatment following the publication of draft guidance by NICE.
In new draft guidance, polatuzumab vedotin (Polivy; Roche) with rituximab and bendamustine has been recommended as a treatment option for adults with diffuse large B-cell lymphoma.
The combination treatment will be available from today for patients whose cancer has relapsed or not responded to primary treatment, and who cannot have a haematopoietic stem cell transplant.
